Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 43.36
- Piotroski Score 4.00
- Grade Overweight
- Symbol (JANX)
- Company Janux Therapeutics, Inc.
- Price $45.45
- Changes Percentage (-1.73%)
- Change -$0.8
- Day Low $44.35
- Day High $47.02
- Year High $65.60
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $62.50
- High Stock Price Target $70.00
- Low Stock Price Target $42.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.20
- Trailing P/E Ratio -36.8
- Forward P/E Ratio -36.8
- P/E Growth -36.8
- Net Income $-58,293,000
Income Statement
Quarterly
Annual
Latest News of JANX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?
The article discusses the top-performing small-cap stocks in 2024, focusing on Janux Therapeutics Inc. (NASDAQ:JANX). Despite the Fed rate cut, the market shows optimism....
By Yahoo! Finance | 4 days ago -
Janux Therapeutics, Inc. (JANX): Among Hedge Funds' Top Biotech Stock Picks
The article discusses the risks and potential rewards of investing in biotechnology stocks, focusing on Janux Therapeutics, Inc. (NASDAQ:JANX) and its drug development projects....
By Yahoo! Finance | 2 weeks ago
